MENINGOCOCCAL DISEASE IN THE RUSSIAN FEDERATION: A TEN-YEAR FOLLOW-UP
- Authors: Koroleva M.A.1, Gritsay M.I.1, Koroleva I.S.1, Melnikova A.A.2
-
Affiliations:
- Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being
- Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being
- Issue: Vol 12, No 2 (2022)
- Pages: 6-11
- Section: Articles
- URL: https://journals.eco-vector.com/2226-6976/article/view/287916
- DOI: https://doi.org/10.18565/epidem.2022.12.2.6-11
- ID: 287916
Cite item
Open Access
Access granted
Abstract
The data accumulated during a long follow-up period could determine the rate, trends, and structure of morbidity, mortality, and death in invasive meningococcal disease (IMD) in the Russian Federation (RF). Objective. To analyze the epidemiological features of IMD in the RF during a 10-year follow-up period. Materials and methods. The personalized information on 10,119 cases of IMD, which had been obtained by the Russian Reference Center for Monitoring Bacterial Meningitis (RCMBM) in 2010-2019, was retrospectively analyzed. Results. The incidence of IMD in the RF tends to decrease. However, since 2016 there has been a rise in the incidence of IMD with an average annual increase of 10.4% and an absolute increase of 0.15 per 100,000population; the involvement of adolescents and young adults in the epidemic process (a rise in the 2016-2019 incidence by 2.4 and 2.6 times, respectively); a 5.5-fold increase in the number of cases caused by serogroup A meningococcal strains. The highest morbidity and mortality rates were found among the children, but the role of adults was significant in the structure of morbidity and mortality for IMD. Conclusion. The investigation has established the precursors of epidemiological troubles in relation to IMD, indicating a possible threat of the next periodic rise in its incidence. The findings could optimize MD vaccination in the RF and increase its coverage among the population
Full Text
About the authors
Maria A. Koroleva
Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being
Email: korolevamaria389@gmail.com
Cand. Med. Sci., Senior Researcher, Laboratory for Epidemiology of Meningococcal Disease and Purulent Bacterial Meningitides Moscow, Russia
Maria I. Gritsay
Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being
Email: maria-griz@mail.ru
Postgraduate Student, Laboratory for Epidemiology of Meningococcal Disease and Purulent Bacterial Meningitides Moscow, Russia
Irina S. Koroleva
Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being
Email: irina-korol@yandex.ru
Laboratory for Epidemiology of Meningococcal Infection and Purulent Bacterial Meningitis Moscow, Russia
Albina A. Melnikova
Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being
Email: melnikova_aa@gsen.ru
Cand. Med. Sci., Deputy Head, Epidemiological Surveillance Directorate Moscow, Russia
References
- Pace D., Pollard A.J. Meningococcal disease: clinical presentation and sequelae. Vaccine 2012; 30(suppl 2): B3-9. doi: 10.1016/j.vaccine. 2011.12.062
- Jafri R.Z., Ali A., Messonnier N.E., Tevi-Benissan C., Durrheim D., Eskola J. et al. Global epidemiology of invasive meningococcal disease. Popul Health Metr. 2013; 11: 17. doi: 10.1186/1478-7954-11-17
- Sridhar S., Greenwood B., Head C., Plotkin S.A., Shfadi M.A., Saha S. et al. Global incidence of serogroup B invasive meningococcal disease: a systematic review. The Lancet Infectious Diseases 2015; 15(11): 1334-46. doi: 10.1016/S1473-3099(15)00217-0
- Harrison L.H., Trotter C.L., Ramsay M.E. Global epidemiology of meningococcal disease. Vaccine 2009; 27(Suppl. 2): B51-63. DOI: 10.1016/j. vaccine.2009.04.063
- Borrow R., Alarcdn P., Carlos J., Caugant D.A., Christensen H., Debbag R. et al. The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection. Exp. Rev. Vaccines 2017; 16(4): 313- 28. doi: 10.1080/14760584.2017.1258308
- Lundbo L.F., Benfield T. Risk factors for community-acquired bacterial meningitis. Infect. Dis. (Lond.). 2017; 49(6): 433-44.
- Cohn A.C., MacNeil J.R., Clark T.A., Ortega-Sanchez I.R., Briere E.Z., Cody Meissner H. et al. Prevention and control of meningococcal disease recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2013; 62(2): 1-32.
- Jansen A., Sanders E., Van Der Ende A., Van Loon A.M., Hoes A.W., Hak E. Invasive pneumococcal and meningococcal disease: association with influenza virus and respiratory syncytial virus activity? Epidemiol. Infect. 2008; 136(11): 1448-54. DOI: 10.1017/ S0950268807000271
- Cohen A.L., McMorrow M., Walaza S., Cohen C., Tempia S., Alexander-Scott M. et al. Potential impact of co-infections and co-morbidities prevalent in Africa on influenza severity and frequency: A systematic review. PLoS ONE 2015; 10(6): e0128580. doi: 10.1371/journal. pone.0128580
- Vipond C., Care R., Feavers I.M. History of meningococcal vaccines and their serological correlates of protection. Vaccine 2012; 30(Suppl. 2): B10-7. doi: 10.1016/j.vaccine.2011.12.060
- Королева М.А., Грицай М.И., Миронов К.О., Ярыгина Е.А., Валдохина А.В., Янушевич Ю.Г. и др. Эпидемиологические проявления вспышки менингококковой инфекции, обусловленной Neisseria meningitidis серогруппы А, в Новосибирске в 2019 г. Эпидемиол. инфекц. болезни. Актуал. вопр. 2021; 11(2): 13-21. doi: 10.18565/epidem. 2021.11.2.13-21
Supplementary files
